Engineers Gate Manager LP Acquires 24,992 Shares of Agios Pharmaceuticals, Inc. $AGIO

Engineers Gate Manager LP grew its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 86.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,912 shares of the biopharmaceutical company’s stock after buying an additional 24,992 shares during the quarter. Engineers Gate Manager LP’s holdings in Agios Pharmaceuticals were worth $2,001,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Nykredit A S acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $26,000. Quantinno Capital Management LP boosted its stake in Agios Pharmaceuticals by 2.7% during the 1st quarter. Quantinno Capital Management LP now owns 27,591 shares of the biopharmaceutical company’s stock valued at $933,000 after purchasing an additional 736 shares during the last quarter. AlphaCentric Advisors LLC increased its holdings in Agios Pharmaceuticals by 6.3% during the 1st quarter. AlphaCentric Advisors LLC now owns 13,971 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 830 shares in the last quarter. ProShare Advisors LLC increased its holdings in Agios Pharmaceuticals by 10.0% during the 4th quarter. ProShare Advisors LLC now owns 12,897 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $43,000.

Agios Pharmaceuticals Trading Down 1.2%

AGIO stock opened at $32.81 on Wednesday. The stock has a market cap of $1.96 billion, a P/E ratio of -4.68 and a beta of 0.60. The stock’s fifty day simple moving average is $34.95 and its two-hundred day simple moving average is $32.08. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AGIO has been the topic of several analyst reports. Bank of America lifted their target price on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Truist Financial lowered their price target on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research report on Friday, July 31st. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, HC Wainwright increased their target price on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.25.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the sale, the insider owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.